peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Biopharma announces planned departure of Chief Financial Officer Donato Spota

27 Nov 2023, 07:00
Regulatory information

Lund, Sweden, 27 November 2023. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Donato Spota, Chief Financial Officer (CFO) has decided to leave the company for private reasons. His last day will be 28 February 2024. A search is underway for a new Chief Financial Officer (CFO).

Søren Tulstrup, President and CEO, Hansa Biopharma said: “Donato has been an integral member of the executive committee and a senior leader within Hansa for the past five years and has played an important role in helping transform Hansa into an integrated, commercial-stage company. We have been fortunate to have benefitted from Donato’s strong expertise and skill set in navigating complex, global financial transactions and multi-national markets and he will be missed as a member of the Hansa team.”

Donato Spota, CFO, Hansa Biopharma said: “It has been a privilege to be part of the Hansa team over a period when the Company has made significant progress in delivering its mission to bring life-altering and life-saving medicines to the patients who need it most. My tenure at Hansa has been exciting and while it is bittersweet to leave the organization, I am looking forward to spending time with my family and watching the organization continue to drive ahead the important work it is doing on behalf of patients.”

--- ENDS ---

Contacts for more information:

Klaus Sindahl, Head of Investor Relations
M: +46 (0) 709 298 269

Stephanie Kenney, VP Global Corporate Affairs
M: +1 (484) 319 2802

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at